Many readers may have been surprised to see Christopher James, the founder of Engine No.
Keep Reading →
March 22 - Hedge Funds, Insider Trading - Comments
Ken Griffin’s Citadel expects to have most of its U.S.
Keep Reading →
May 4 - Hedge Funds, Insider Trading - Comments
Insiders are masters of snatching up shares of their companies at a discount, expanding their positions during weakness in the stock.
Keep Reading →
June 18 - Insider Trading, Market Movers, News - Comments
The five opioid treatment stocks are among several companies that have taken their own approach to the growing opioid addiction market in the US, which also happens to be the...
Keep Reading →
February 5 - Lists, News - Comments
Curious to know which treatments are among the 15 bestselling most profitable drugs of all time? The pharmaceutical industry has been a topic of interest for investors, market...
Keep Reading →
November 24 - News - Comments
"U.S. equities rose on Monday as a weekend filled with geopolitical worries ended more calmly than investors expected, while bank stocks charged ahead.
Keep Reading →
April 17 - Commodities, Gold, Market Movers, News, Tech - Comments
Detailed results from the IXORA-S study have revealed that Taltz (ixekizumab) has superior efficacy compared to Stelara (ustekinumab).
Keep Reading →
March 8 - News, Stock Analysis - Comments
A few weeks ago, President Donald Trump met with a series of biotech CEOs to discuss a historically major pain point for the industry: cutting the FDA drug approval process "at...
Keep Reading →
February 23 - News, Stock Analysis - Comments
The once per week Trulicity label from Eli Lilly and Co (NYSE:LLY) has been updated. The changes, which have been approved by the U.S.
Keep Reading →
February 9 - News, Stock Analysis - Comments
Acorda Therapeutics Inc (NASDAQ:ACOR) inhaled migraine candidate CVT-427 is seen by Janney analyst Ken Trbovich as likely to give Eli Lilly and Co (NYSE:LLY) severe competition...
Keep Reading →
January 24 - News, Stock Analysis - Comments
Eli Lilly and Co (NYSE:LLY) just announced that it is set to acquire junior biotech CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) in a deal worth up to $960 million.
Keep Reading →
January 19 - News, Stock Analysis - Comments
The problem of obesity is a modern one, with large sections of the global population becoming overweight late in the 20th century and into the 21st, and the prevalence is especially...
Keep Reading →
January 17 - Lists, News - Comments
After a strong 2015, health care stocks are leading the way lower in 2016. And it’s been an even uglier year for biotechnology company Gilead Sciences, Inc.
Keep Reading →
December 23 - News, Stock Analysis - Comments
“By diligently prioritizing, we will continue to successfully launch and commercialize new medicines, meet the needs of our customers and patients, and ultimately help AstraZeneca...
Keep Reading →
December 9 - News, Stock Analysis - Comments
Eli Lilly and Co (NYSE:LLY) has recently confirmed that it will cut jobs following the release of disappointing results from a clinical trial evaluating solanezumab, affecting...
Keep Reading →
December 8 - News, Stock Analysis - Comments
As the markets take a break for Thanksgiving, things settled down a little bit late-Wednesday, but not before some sharp shocks in the biotech sector.
Keep Reading →
November 24 - Market Movers, News, Stock Analysis - Comments
Biogen Inc (NASDAQ:BIIB) stock is getting whacked in sympathy to Eli Lilly and Co (NYSE:LLY)'s announcement that it has once again failed in its quest to prove solanezumab to ...
Keep Reading →
November 23 - News, Stock Analysis - Comments
Eli Lilly And Co (NYSE:LLY) is having an incredibly rough day in the market today.
Keep Reading →
November 23 - News, Stock Analysis - Comments
On the day before Thanksgiving, five stocks, First Solar, Inc.
Keep Reading →
November 23 - News - Comments
The Humulin R U-500 insulin is prescribed to patients who need a higher dose of insulin on a daily basis.
Keep Reading →
November 10 - News, Stock Analysis - Comments
Eli Lilly and Co (NYSE:LLY) has categorically stated to its regulators and investors that it is hanging onto a possible nod from the FDA for a new indication for Jardiance.
Keep Reading →
November 2 - News, Stock Analysis - Comments
Although his family office isn't technically a hedge fund anymore (a settlement with the SEC saw to that), many on Wall Street still regard billionaire Steve Cohen's Point72 ...
Keep Reading →
September 19 - Dividend Stocks, Hedge Fund Analysis, Hedge Funds, News - Comments
On June 28, 2016, the Endocrinologic and Metabolic Drugs Advisory Committee of the Food and Drug Administration (FDA) met to discuss and vote upon a supplemental New Drug Application...
Keep Reading →
September 9 - News, Stock Analysis - Comments
Eli Lilly and Co (NYSE:LLY) is one of the largest drug companies in the world. In this article, we'll take a closer look at why many hedge funds are long the drug company.
Keep Reading →
September 2 - Hedge Funds, News, Stock Analysis - Comments
Peter Lynch, the former manager of the Magellan Fund at Fidelity Investments, once said that “Insiders might sell their shares for any number of reasons, but they buy them for...
Keep Reading →
August 17 - Insider Trading, News - Comments
Among the stocks traders are talking about are BP plc (ADR) (NYSE:BP), Valero Energy Corporation (NYSE:VLO), CONSOL Energy Inc.
Keep Reading →
July 26 - Earnings Report, News, Tech - Comments
Billionaire Andreas Halversen's Viking Global has generated outstanding returns for its investors ever since its inception in 1999, ranking as one of the most successful pure...
Keep Reading →
July 25 - Hedge Fund Analysis, Hedge Funds, News - Comments
At the turn of the millennium, the population of the United States clocked in at 282.2 million.
Keep Reading →
June 22 - News, Stock Analysis - Comments
There's been a slew of earnings reports come in over the past 24 hours, with Procter & Gamble Co (NYSE:PG), 3M Co (NYSE:MMM), E I Du Pont De Nemours And Co (NYSE:DD), Coach Inc...
Keep Reading →
April 26 - Market Movers, News - Comments
U.S equities’ awful start to 2016 is gradually getting even worse, which could make investors conclude that the ratio of insider selling to insider buying has dropped significantly...
Keep Reading →
February 9 - Insider Trading, News - Comments
In a career spanning over three and a half decades, billionaire Steve Cohen has made a name for himself as being one of the best traders in the world.
Keep Reading →
January 7 - Dividend Stocks, Hedge Funds, News - Comments
With the VIX above 20 and many investors on edge over the jump in volatility in recent days, Eli Lilly and Co (NYSE:LLY), Willis Towers Watson (NASDAQ:WLTW), Amazon.com, Inc.
Keep Reading →
January 5 - Market Movers, News, Tech - Comments
Steve Cohen built a strong reputation and personal fortune for himself while managing hedge fund S.A.C Capital Advisors from 1992 until early 2014, when the fund was converted...
Keep Reading →
November 19 - Hedge Fund Analysis, Hedge Funds, News - Comments
The week’s trading is underway and several biotech stocks are hot out of the gates, making big early morning gains.
Keep Reading →
October 12 - Hedge Funds, Market Movers, News - Comments
Eli Lilly and Co (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY) are experiencing volatility at Tuesday’s open, initially moving in different directions before both started ...
Keep Reading →
September 29 - Market Movers, News - Comments
Top picks for Monday's trading by CNBC's Fast Money Crew seem to be across the board.
Keep Reading →
January 11 - News, Tech - Comments
The loss of Patents over the years, has been the main cause of lower earnings at Eli Lilly and Co (NYSE:LLY), the CEO of the company, Dr.
Keep Reading →
July 24 - News - Comments
